Acute Leukemia French Association (ALFA)

Prof. Hervé Dombret

The ALFA group (Acute Leukemia French Association) is a multidisciplinary association of clinicians, biologists, and clinical research assistants (Loi 1901 according to the French Law) interested in the treatment of adult patients with Acute Myeloid Leukemia (AML) and conducting research works in this field.

FIM

Prof. Jean-Jacques Kiladjian

The FIM is a cooperative group of clinicians, biologists and researchers from all over France involved in the diagnosis, management, treatment and research on Ph-negative myeloproliferative disorders.

French Innovative Leukemia Organization (FILO)

Prof. Arnaud Pigneux

The FILO Group "French Innovative Leukemia Organization" encompassed a board of directors and two scientific councils identified as "FILO-LAM" and "FILO-LLC".

The FILO group includes more than 80 investigating centres (35 of which are experts in AML): university hospitals, hospitals or private centres throughout France and Belgium.

GRAALL

Prof. Nicolas Boissel

The GRAALL aims to develop scientific knowledge on Leukemias Acute Lymphoblastic Diseases (ALL) of adults and their treatment in order to improve the survival of patients.

Groupe Francophone des Myélodysplasies (GFM)

Prof. Pierre Fenaux

The purpose of the GFM is to implement, carry out and sponsor all clinical, epidemiological, pharmacological and biological research in the field of Myelodysplastic Syndromes (MDS), as well as all educational and / or informative actions for the medical profession and patients. The GFM brings together all the French, European and other French-s…

SFCE

Prof. Arnaud Petit

The SFCE is an association of health professionals (surgeons, radiotherapists, radiologists, pathologists, biologists, nurses, researchers) dedicated to improving the understanding, diagnosis, treatment and follow-up of cancers in children and adolescents, particularly childhood leukaemia. It brings together a total of over 500 members from 30 …

CANTHER (UMR-9020/1277)

Prof. Salomon Manier

Our research team, entitled « Factors of persistence of leukemic cells », is devoted to the discovery of factors that contribute to long-term persistence of leukemia cells, such as tumor dormancy, and to the characterization of predictive genomic markers of hematological malignancies evolution. 

The team is located at t…

CRCM / IPC (UMR-1068)

Prof. Norbert Vey

The center de Recherche en Cancérologie de Marseille (CRCM) and the Institut Paoli-Calmettes (IPC) are two research entities based in Marseille. In the field of leukemias and related diseases, the CRCM-IPC addresses the following research themes: genomics, leukemogenesis, immune monitoring/immunotherapy, cell therapy, advanced therapy me…

IDMIT (UMR-1184)

Dr. Stéphane Prost

Our entity aims to characterize the involvement of PPAR-γ nuclear receptor in normal and pathological hematopoiesis with a particular emphasis on the therapeutic potential of PPAR-γ agonists in the management of myeloid neoplams.

U1069-N2COx

Prof. Olivier Hérault

Leukemia cells are in close interaction with the bone marrow microenvironment within hypoxic leukemic niches highly involved in relapse, and N2COx is focusing its research on their role in leukemogenesis. Affiliated to the French national institute of health and medical research (INSERM) and the University of Tours, the research team (CHRU and …

C3M (UMR-1065)

Dr. Patrick Auberger

Based in Nice, the Mediterranean Center for Molecular Medicine (C3M) treats cancers, metabolic and inflammatory diseases. Its teams have an imaging, genomics and cytometry facility.

CRCT (UMR-1037)

Dr. Jean-Emmanuel Sarry

The Centre de Recherche en Cancérologie de Toulouse (CRCT) houses two teams dedicated to Leukemias and related diseases: 

The IGAALD team  - Impact Of Genetic Alterations On Acute Leukemia Development - led by Pr Eric Delabesse whose research focuses on the biological mechanisms by whic…

CRSA (UMR-938)

Prof. François Delhommeau

The UMR-938 (Saint-Antoine research center, CRSA) houses the "Hematopoietic and leukemic development" team led by Prof. François Delhommeau. This team focuses on the following research themes: myeloid leukemia, hematopoiesis, erythropoiesis.

EMiLy (INSERM U1160)

Dr. Karl Balabanian

The Team 1 “Homeostatic and Pathological Chemokine-Regulated Interplays between Lymphocytes and their Microenvironment” focuses its research on the following fields: immunology, hematology, oncology, bone marrow microenvironment in health and leukemic diseases.

GenCellDis (UMR-944)

Prof. Jean Soulier

Six teams of the INSERM/CNRS U944/UMR7212 "Genomes and Cell Biology Therapeutics" unit (GenCellDis) focus on research into acute leukemia and related syndromes.

Gustave Roussy (UMR-1170)

Dr. Virginie Penard-Lacronique

The unit is interested in investigating the consequences of the somatic mutations occurring early in transformation of human hematopoietic progenitors in natural situation (primary samples) and in treatment condition (clinical trials). 

Team 1 : Hematopoietic transformation, epigenetic and transcription factors

Team 2: Biol…

INSERM UMR-S 1131 (UMR-1131)

Prof. Stéphane Giraudier

The INSERM UMR-S 1131 unit focuses its research on normal and pathological hematopoiesis: emergence, environment and translational research. In the past, the unit has focused on basic research and patient-oriented research in the field of myeloid malignancies. By working on unmet clinical needs, it has made important contributions to this field…

Cochin Institute (UMR-1016)

Prof. Michaela Fontenay

The field of research of the team focus on the study of normal myeloid development, from the hematopoietic stem cell to the mature erythroblast and their pathological counterparts in myelodysplastic syndromes and acute myeloid leukemias, to identify mechanisms of the diseases and therapeutic targets.

U1312 BRIC

Dr. Jean-max Pasquet

Team N°10 of BoRdeaux Institute of onCology (BRIC) INSERM unit 1312 “Normal and Leukemic Hematopoietic Stem Cells: persistence, signaling and therapeutic targets” brings together several researchers, biologists and physicians to develop a fundamental and translational research on acute myeloblastic leukemia (AML).

BRIC i…

U976 - HIPI

Dr. Jean-Christophe Bories

The U976 unit (directed by Jean Christophe Bories) works on Human Systems Immunology & Inflammatory Networks. Its research topics also include systems biology and medicine, Bioinformatics, human inflammatory and neoplastic diseases, translational research.

UMR - 1274

Dr. Françoise Pflumio

The team Niche and cancer in hematopoiesis, directed by Françoise Pflumio, is supported by Inserm, CEA, University of Paris and University Paris-Saclay. 

The entity is interested in the molecular mechanisms that drive transformation and propagation of leukemic cells in mouse and humans, the interactions between the bone marr…

UMR-1098 RIGHT

Prof. Olivier Adotevi

The UMR-1098 RIGHT works on biomarker identification and development of new therapeutic approaches mainly based on biological drugs to treat cancer (leukemias, in relationship with the OPALE Carnot Institute) or inflammatory diseases (graft-versus-host disease after allogeneic hematopoietic cell transplantation in relationship with the OPALE Ca…

URP-3518

Prof. Hervé Dombret

The Research Unit (URP)-3518, University of Paris: " Clinical Research in hematology, Immunology and Transplantation " proposes:

Clinical and bioclinical research studies based on IHUB-2 THEMA and RIME (Registre des Insuffisances Médullaires) cohorts of patients with leukemia and related disorders

Partnership research pro…

CIC-Marseille-Biotherapy

Prof. Christian Chabannon

Through its "Biotherapies" module, the center is involved in the development and validation of cell and gene therapies produced by engineering cells of hematopoietic origin, anti-cancer cellular immunotherapies and regenerative therapies for hematopoietic tissue.

MEARY CIC-BT

Prof. Jerome Larghero

The MEARY CIC-BT Cell and Gene Therapy Center is dedicated to the manufacturing of advanced therapy medicinal products (ATMP) for serious, chronic or rare diseases, such as leukemias.

MEARY R&D - GENOMICS & BIONFORMATICS

Prof. François Sigaux

The MEARY Research, Development, Genomics and Bioinformatics platform is designed to help research teams develop third generation genomics, bioinformatics and artificial intelligence technologies.